Puritan Medical v. Copan Italia: Federal Circuit Dismisses Swab Patent Appeal
Puritan Medical Products and its affiliates brought a five-patent infringement action against Copan Italia and Copan Diagnostics over flocked swab technology used for biological specimen collection. After 687 days, the Federal Circuit dismissed the appeal for lack of jurisdiction, finding the collateral order doctrine’s threshold requirement unmet.
Jurisdiction, not infringement, ends Puritan’s Federal Circuit appeal
Filed on 27 June 2022, Case No. 22-1943 pits Puritan Medical Products Company LLC, Hardwood Products Company LLC and LP, Puritan Medical Products Company I LP, and Puritan Diagnostics LLC (collectively, Puritan) against Copan Italia SPA and its US subsidiary Copan Diagnostics Inc. The dispute centres on five granted US patents — US8979784B2, US9173779B2, US8317728B2, US8114027B2, and US9011358B2 — covering flocked swab designs and methods for collecting biological specimens, a product category that gained heightened commercial significance during the COVID-19 pandemic.
The Federal Circuit closed the case on 14 May 2024, dismissing the appeal for lack of jurisdiction rather than on the merits. The court found that the first requirement of the collateral order doctrine — a threshold test for appellate jurisdiction over interlocutory orders — had not been satisfied, making it unnecessary to evaluate the remaining factors. The practical effect is that neither party received a substantive ruling on patent validity or infringement at the appellate level.
The 687-day duration from filing to dismissal is consistent with the Federal Circuit’s docket pace for jurisdictional disputes, though the absence of a merits decision is notable given the scale of the patent portfolio asserted. The dismissal for lack of jurisdiction suggests the appeal targeted an interlocutory order that did not meet the stringent collateral order threshold. What drove the original district-court posture prompting the appeal, and whether Puritan pursues further action, remains unknown from the public record.
Filing to Appeal Dismissed in 687 days
687 days — longer than the median Federal Circuit appeal resolution window
Appeal dismissed for lack of jurisdiction: what it means for both parties
Collateral order doctrine: a narrow jurisdictional gateway
The collateral order doctrine permits appellate review of certain interlocutory orders before final judgment. To apply, the order must (1) conclusively resolve a disputed question, (2) resolve an important issue completely separate from the merits, and (3) be effectively unreviewable on appeal from final judgment. The Federal Circuit found the first element absent, ending the appeal before any merits analysis. This is a procedural dismissal — the underlying infringement claims were never adjudicated at this level.
Jurisdictional dismissalPuritan’s appeal ends without a merits win or loss
For Puritan Medical Products and its affiliates, the dismissal means no appellate validation of their five-patent portfolio. The underlying district court proceedings remain the operative forum for resolving infringement and validity. Puritan retains the ability to raise the same arguments once a final district court judgment is entered, at which point a full appeal on the merits becomes available. The patents themselves remain in force and enforceable pending any future validity challenge.
No merits ruling — appeal path preservedCopan avoids appellate merits scrutiny for now
Copan Italia and Copan Diagnostics benefit from the dismissal in the sense that no appellate ruling on infringement or validity has been entered against them. However, the dismissal equally provides no affirmative protection: the Federal Circuit issued no finding that Copan does not infringe or that the patents are invalid. Copan continues to face the underlying district court action, and the jurisdictional ruling cannot be used as a substantive defence on the merits.
No merits shield — district risk remainsFlocked swab IP landscape remains unresolved at appellate level
The dismissal leaves the competitive and licensing landscape for flocked swab technology unsettled. With five patents spanning both device design and specimen collection methodology, the Puritan portfolio continues to represent a potential enforcement risk for manufacturers and distributors in the diagnostics swab market. Competitors and OEM suppliers should monitor the underlying district proceedings closely, as a final judgment would open the door to a substantive Federal Circuit ruling on these patents.
Enforcement risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Puritan Medical Products Company, LLC | Company | Medical swab manufacturer and IP licensor — holder of US8979784B2 and four related flocked swab patentsSearch in Eureka ↗ |
| Co-Plaintiff | Hardwood Products Company, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Hardwood Products Company, LP | Company | Search in Eureka ↗ |
| Co-Plaintiff | PURITAN MEDICAL PRODUCTS COMPANY I LP | Company | Search in Eureka ↗ |
| Co-Plaintiff | Puritan Diagnostics, LLC | Company | Search in Eureka ↗ |
| Defendant | Copan Italia, SPA | Individual | Copan Italia SPA, Italian diagnostics manufacturer, and US subsidiary Copan Diagnostics Inc.Search in Eureka ↗ |
| Co-Defendant | Copan Diagnostics, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | James H. Hulme | Attorney | Counsel for Puritan Medical Products Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Janine A. Carlan | Attorney | Counsel for Puritan Medical Products Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kevin R. Pinkney | Attorney | Counsel for Puritan Medical Products Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael L. Scarpati | Attorney | Counsel for Puritan Medical Products Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Taniel E. Anderson | Attorney | Counsel for Puritan Medical Products Company, LLCSearch in Eureka ↗ |
| Plaintiff law firm | ArentFox Schiff LLP | Law Firm | Representing Puritan Medical Products Company, LLCSearch in Eureka ↗ |
| Defendant counsel | Andrew H. DeVoogd | Attorney | Counsel for Copan Italia, SPASearch in Eureka ↗ |
| Defendant counsel | Courtney Patrice Herndon | Attorney | Counsel for Copan Italia, SPASearch in Eureka ↗ |
| Defendant counsel | James M. Wodarski | Attorney | Counsel for Copan Italia, SPASearch in Eureka ↗ |
| Defendant counsel | Michael Newman | Attorney | Counsel for Copan Italia, SPASearch in Eureka ↗ |
| Defendant counsel | Peter Cuomo | Attorney | Counsel for Copan Italia, SPASearch in Eureka ↗ |
| Defendant law firm | Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC | Law Firm | Representing Copan Italia, SPASearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s ruling is procedural and narrow: by finding the first collateral order factor unmet, the court declined to reach the merits of the infringement dispute entirely. The phrasing ‘we need not consider whether the additional factors have been established’ indicates a threshold-only analysis — the court expressly avoided any commentary on the underlying validity or infringement questions. This leaves the district court as the exclusive forum for substantive resolution, and neither party can claim a precedential advantage from this appellate outcome.
US8979784B2 — Flocked swab design and biological specimen collection methods
The five patents at the centre of this dispute — US8979784B2, US9173779B2, US8317728B2, US8114027B2, and US9011358B2 — cover both the physical architecture of flocked swabs and the methods by which they are used to collect biological specimens. Flocked swabs feature fibres applied perpendicular to the swab tip, improving specimen absorption and release compared to traditional wound-fibre designs. The application dates span multiple filing windows, suggesting a deliberate prosecution strategy to build layered coverage around the core technology platform.
This portfolio carries significant commercial weight in the in-vitro diagnostics sector. Flocked swabs became a globally critical supply item during the COVID-19 pandemic, with Puritan and Copan among the leading manufacturers. Holding both device and method claims across five patents creates broad enforcement reach: a competitor cannot easily design around device claims alone without also addressing method claim exposure. For any company manufacturing, importing, or distributing flocked swabs for clinical, diagnostic, or research use, this portfolio warrants careful FTO attention.
Should you run an FTO against US8979784B2 and the Puritan flocked swab portfolio?
Any manufacturer, distributor, or OEM supplier of flocked swabs for biological specimen collection — including those serving clinical laboratories, hospital networks, public health agencies, or point-of-care testing providers — should consider a formal FTO analysis against this five-patent portfolio. The combination of device and method claims means that product design changes alone may be insufficient to clear all infringement risk. The ongoing district court proceedings further elevate the urgency of clearance.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map claim scope across all five patents simultaneously, identify cited prior art, and surface design-around pathways. Eureka’s semantic claim analysis can flag which product configurations present the highest overlap with independent claims — providing actionable clearance intelligence before the district court issues a final ruling that could reshape the competitive landscape.
Run a freedom-to-operate analysis on US8979784B2 to assess your product’s exposure
Run FTO in Eureka →Similar flocked swab and diagnostics device patent cases at the Federal Circuit
Explore comparable Federal Circuit infringement appeals involving diagnostic swab, specimen collection, and in-vitro diagnostics device patents — including jurisdictional dismissals and merits rulings.
What this case signals for the diagnostics swab IP landscape
A jurisdictional dismissal at the Federal Circuit keeps five flocked swab patents in active play — and the district court battle unresolved.
Collateral order appeals in patent cases face a very high bar
This dismissal reinforces that interlocutory appeals in patent infringement actions rarely survive Federal Circuit jurisdictional scrutiny. IP counsel pursuing mid-case appeals should rigorously assess all three collateral order factors before filing — failure at the threshold means 687 days of appellate litigation yields no substantive result for either party.
Five-patent portfolios create layered enforcement leverage
Puritan’s assertion of five related patents across swab design and methodology signals a portfolio-based enforcement strategy. For competitors in the diagnostic swab and specimen collection space, a single design clearance is insufficient — FTO analysis must span both device architecture and method claims across the full portfolio to reliably assess exposure.
Puritan v Copan — key questions answered
The Federal Circuit dismissed the appeal for lack of jurisdiction because the first requirement of the collateral order doctrine was not satisfied. The collateral order doctrine allows interlocutory appeals only where an order conclusively resolves a distinct issue, among other requirements. Because the threshold element failed, the court declined to evaluate the remaining factors and dismissed without reaching the merits of the underlying flocked swab patent infringement claims.
Puritan asserted five US patents: US8979784B2, US9173779B2, US8317728B2, US8114027B2, and US9011358B2. These patents cover flocked swab device designs and methods of using flocked swabs for collecting biological specimens, spanning multiple application filing dates consistent with a layered portfolio prosecution strategy.
A jurisdictional dismissal at the Federal Circuit means no merits ruling was issued on validity or infringement. The underlying district court proceedings remain active and are the operative forum. Neither party gains a substantive advantage from the appellate dismissal. Once the district court enters a final judgment, a standard merits appeal to the Federal Circuit becomes available to the losing party.
The collateral order doctrine is a narrow exception allowing appellate review of certain interlocutory orders before final judgment. For it to apply, the order must conclusively resolve a disputed question, address an important issue completely separate from the merits, and be effectively unreviewable after final judgment. In patent cases, the doctrine is rarely satisfied, and the Federal Circuit consistently applies it strictly — as illustrated by the dismissal in this case at the first factor alone.
The patents at issue cover flocked swabs designed for collecting biological specimens, including both the physical device architecture — featuring fibres applied perpendicularly to the swab tip for improved specimen absorption and release — and the methods by which such swabs are used in specimen collection procedures. These products are widely used in clinical diagnostics, COVID-19 testing, microbiology, and other laboratory specimen collection applications.
PatSnap Eureka searches patents and litigation data to answer instantly.